Physician profile
David E Holloway
NPI 1821195777
$14,236.68
in general payments reported to CMS, 2019-2025
32 companies · $3,091 in 2025
The $3,091 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,950 · 2020: $1,336 · 2021: $2,151 · 2022: $1,315 · 2023: $2,192 · 2024: $2,201 · 2025: $3,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,478 · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,477.55 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,133.80 | 2019-2025 | Trintellix |
| Lundbeck LLC | $2,020.49 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Otsuka America Pharmaceutical, INC. | $1,343.44 | 2019-2025 | Rexulti, Abilify Mycite |
| Abbvie INC. | $1,343.19 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,072.50 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $888.70 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $688.23 | 2020-2025 | Caplyta |
| Allergan, INC. | $540.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $508.02 | 2019-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $425.13 | 2023-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $397.52 | 2022-2025 | Auvelity |
| Almatica Pharma LLC | $348.61 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Corium, LLC | $348.29 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $312.14 | 2019-2023 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $285.88 | 2025 | Cobenfy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $228.45 | 2019-2023 | Jornay Pm |
| Adlon Therapeutics L.P. | $211.21 | 2019-2021 | |
| Shire North American Group INC | $195.39 | 2019 | |
| Alkermes, INC. | $188.11 | 2021-2024 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $115.60 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $100.25 | 2024-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $77.81 | 2022-2023 | Quviviq |
| Noven Therapeutics, LLC | $75.59 | 2020-2024 | Secuado, Xelstrym |
| Sage Therapeutics, LLC | $73.18 | 2024-2025 | Zurzuvae |
| Jazz Pharmaceuticals INC. | $73.06 | 2019-2021 | |
| Harmony Biosciences LLC | $62.44 | 2022 | |
| Collegium Pharmaceutical, INC. | $59.57 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $47.21 | 2019 | |
| Neuronetics, INC. | $32.17 | 2019-2023 | Neurostar Tms Therapy System |
| Owp Pharmaceuticals, INC. | $15.06 | 2019 | |
| Eisai INC. | $13.70 | 2020 | |
| Neos Therapeutics, LP | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Holloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.